- Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway
Na Li et al, 2021, World Journal of Gastrointestinal Oncology CrossRef - Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology
Adrianna Zygmunt et al, 2024, Expert Opinion on Drug Delivery CrossRef - Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
Min Sun et al, 2024, Frontiers in Pharmacology CrossRef - Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau et al, 2021, Reviews in Endocrine and Metabolic Disorders CrossRef - Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice
Jessica M. Snyder et al, 2023, GeroScience CrossRef - Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
Hui‐Lin Sung et al, 2024, Diabetes/Metabolism Research and Reviews CrossRef - The role of metabolic reprogramming in pancreatic cancer chemoresistance
Chang Liu et al, 2023, Frontiers in Pharmacology CrossRef - Diabetes and pancreatic cancer: Exploring the two-way traffic
Ayan Roy et al, 2021, World Journal of Gastroenterology CrossRef - Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK
Kenji Shoda et al, 2023, Cellular and Molecular Neurobiology CrossRef - Redirection to the Drug Discovery: Antidiabetic Drugs Repurposing in Cancer
Prajakta Bule et al, 2024, Drug Repurposing CrossRef